Risk of Thromboembolic Events and Anti-EGFR Agents
In conclusion, we have observed that anti-EGFR MoAbs C and P are associated with a significant increase in the risk of venous but not of arterial thromboembolism in advanced solid tumors. In particular, they increase the risk of VTEs in patients treated with both anti-EGFR MoAb and platinum-based chemotherapy. Clinicians should be aware of the increase in VTEs, especially in patients with colorectal and head and neck cancer settings, where these drugs are currently labeled. Careful surveillance and prompt reporting of these serious vascular events are crucial and, at the same time, thromboprophylaxis could be a challenge for the future.
Conclusion
In conclusion, we have observed that anti-EGFR MoAbs C and P are associated with a significant increase in the risk of venous but not of arterial thromboembolism in advanced solid tumors. In particular, they increase the risk of VTEs in patients treated with both anti-EGFR MoAb and platinum-based chemotherapy. Clinicians should be aware of the increase in VTEs, especially in patients with colorectal and head and neck cancer settings, where these drugs are currently labeled. Careful surveillance and prompt reporting of these serious vascular events are crucial and, at the same time, thromboprophylaxis could be a challenge for the future.
SHARE
![Breast Cancer Screening (PDQ®): Screening - Health Professional Information [NCI]-Special Population](https://cdnus.oss-us-west-1.aliyuncs.com/libs/images/NewsJpg/cate_6/039_215x160.jpg)
